Form 4 for LXEO Lexeo Therapeutics, Inc.
Accepted 2026-07-01 18:49:07 ET · period of report 2026-06-29 · accession 0002024096-26-000011 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-01 18:49 | 2026-06-29 | LXEO | Otero Jose Manuel | COO | A - Grant | $0.00 | +12.1K | 142.1K | +9% | $0 | |
| 2026-07-01 18:49 | 2026-07-01 | LXEO | Otero Jose Manuel | COO | S - Sale | $4.48 | -4,666 | 137.5K | -3% | -$20.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-29 | A | A | 12,060 | $0.00 | 142,148 | D | — | — | |
| 2 | Common | Common Stock | 2026-07-01 | S | D | 4,666 | $4.48 | 137,482 | D | — | — | (F1) Represents a sale to cover tax obligations on the release of performance Restricted Stock Units ("RSUs"). (F2) This transaction was executed in multiple trades at prices ranging from $4.35 to $4.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) Includes 100,621 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. |